GLP-1 Drugs Face Lawsuits Over Severe Side Effects

GLP-1 Drugs Face Lawsuits Over Severe Side Effects

New weight-loss drugs, known as GLP-1s, are quickly becoming popular. Eli Lilly’s new weight-loss pill, tirzepatide (branded as Zepbound), was prescribed nearly 1,400 times in its first week.

This follows Novo Nordisk’s approval of a similar pill in December. These pills offer an alternative to the widely used GLP-1 injections like Ozempic and Wegovy.

While the new pills are seeing early success, the FDA is asking for more safety information. They specifically want to know if tirzepatide is linked to liver and heart problems. The FDA stated that the current data isn’t enough to fully understand these potential risks.

This review comes as thousands of patients are suing drug makers. They claim GLP-1 drugs caused severe side effects.

Patient Lawsuits Mount

An estimated 12% of adults in the U.S. have used these medications. Since 2023, at least 4,400 lawsuits have been filed.

Over 1,100 people report that the drugs caused blindness. One Maryland truck driver claims he suffered a stroke that left him blind.

Another serious side effect reported is gastroparesis, a condition causing stomach paralysis. This affects 75% of the plaintiffs, who range in age from 18 to 87. They say gastroparesis has left them with pain, dehydration, and even malnutrition.

Attorney Grace P. Chancellor, who is on the plaintiffs’ executive committee for GLP-1 litigation, discussed these claims.

Manufacturer Responsibility

Drug makers like Eli Lilly and Novo Nordisk state that the drugs’ labels include FDA-approved warnings. However, Chancellor argues this information is not enough.

She stressed that conditions like blindness are not just side effects; they are permanent, life-altering injuries. The labels need to be more specific about these serious risks.

Chancellor explained that while drugs go through FDA approval, manufacturers have a duty. They must report known conditions to the FDA and ensure warnings are adequate.

This duty remains with companies like Novo Nordisk and Eli Lilly to warn about severe outcomes. The drug makers insist that the safety of GLP-1s has been proven in clinical trials and reviewed by the FDA many times.

What’s Missing from the Warnings?

Chancellor clarified that the lawsuits are not aiming to remove these drugs from the market. Instead, they seek to ensure patient safety and accurate labeling.

She noted that while these drugs undergo extensive testing, manufacturers are still responsible for updating labels. This includes incorporating information from post-marketing complaints and patient experiences.

She shared a client’s story, Mr. Angle, a Maryland truck driver. After six months on the drug, he woke up unable to see in one eye. His doctor, not seeing a clear connection, advised him to stay on the medication.

Four months later, he lost vision in his second eye. A study suggesting a link to this condition came out later, but the damage was permanent.

Chancellor emphasized that in the U.S., the responsibility for accurate and updated labels lies solely with the manufacturers. They must inform consumers about the real-world consequences of these medications. The litigation is still in its early stages, with cases recently consolidated in federal court.

Expert Perspectives on Safety and Expansion

Dr. Lee, a vascular surgeon and founder of Health Care for Action, agreed that these claims warrant attention. While over 40 trials have been conducted and the FDA has approved the drugs, he acknowledged that new risks can emerge over time. He suggested that certain patient groups might have a higher risk for adverse events like blindness.

Dr. Lee also believes these drugs should remain on the market because they help many people. However, he supports the idea that manufacturers must update labels as new risk factors are identified. He pointed out that the market for these drugs is growing rapidly, with new pill versions now available.

Regarding the rapid expansion, Dr. Lee questioned who is taking these medications. GLP-1s are primarily intended for patients with diabetes or cardiovascular risk factors.

He noted that many people are using them for cosmetic reasons or in settings where proper medical oversight might be lacking. This raises questions about manufacturer liability when drugs are used outside their intended medical scope.

Future Outlook and Market Dynamics

The expiration of key patents for drugs like Novo Nordisk’s semaglutide (Ozempic) is expected to lead to cheaper versions entering the market, particularly from countries like India. This could impact drug prices and access in the U.S. Dr. Lee suggested that while cheaper versions might become available, ensuring their quality and effectiveness will be crucial.

He cautioned that if medications are obtained from outside the country or prescribed in non-medical settings, quality control could be compromised. This could potentially lead to more complications, similar to those reported by patients who have filed lawsuits. The FDA’s role in checking these imported drugs will be important.

Psychedelics and FDA Approval

The discussion also touched upon a recent White House executive order to speed up reviews of certain psychedelic drugs. This action was reportedly influenced by figures like Joe Rogan, who claimed high success rates for addiction treatment with psychedelics.

Dr. Lee expressed caution regarding these claims. While research into psychedelics for conditions like PTSD and addiction is ongoing, he stressed the need for rigorous data.

He found it concerning that expedited FDA approval might be considered based on anecdotal evidence or text messages. Proper research is essential to determine patient benefits, appropriate dosages, and potential negative effects before widespread use.

The upcoming months will likely see continued legal action regarding GLP-1 drugs and increased scrutiny of their long-term safety. The FDA will continue its review of tirzepatide, while courts will hear evidence in the ongoing patient lawsuits.

Source: Lawyer, doctor speak on lawsuit accusing GLP-1 drugs causing severe side effects | NewsNation Prime (YouTube)